Irwin J. Gruverman

IRWIN J. GRUVERMAN is Chairman and Chief Executive Officer of MFIC
Corporation. He has extensive management, financing and technology
experience with scientific product organizations, with emphasis on
engineered products, medical devices, diagnostic tests and radio
pharmaceutical imaging products. He is the Founder of MFIC Corporation,
(formerly Microfluidics International Corporation) and a Founder and
Chairman of North American Scientific, Inc., a leader in producing
brachytherapy radiation sources for treatment of cancer and other
proliferative disorders, in providing collimators and leading software
for intensity-modulated radiation therapy for precise treatment of
malignant tumors and a developer of imaging radiopharmaceuticals for
management of cancer therapy and transplant rejection. He was Executive
Vice President of DuPont’s New England Nuclear Division, in charge of
healthcare activities, and was responsible for the development and
commercial success of Thallium-201 as an imaging diagnostic for heart
disease assessment. He operated a profitable $100 million business
employing 1,200 people, which was acquired by DuPont. Achievements
included establishment of a multi-cyclotron facility to produce medical
radioisotopes and the first commercial linear accelerator designed for
manufacture of such radioisotopes. Mr. Gruverman was the General Partner
of G&G Diagnostics Funds, with a venture arm of Searle (a Monsanto
Company) as the sole limited partner. The funds invested mainly in
medical diagnostic opportunities in the US and Europe, and provided
early stage funding and advisory services for more than 50 ventures. In
12 years of operation, the funds helped more than 15 early-stage
investees in reaching public status.